ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
التفاصيل البيبلوغرافية
العنوان:
ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Context In the present phase II clinical trial (NCT02692248), we investigated the efficacy and toxicity of the combination of ibrutinib with R-GEMOX-D in patients with non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Objective The main objective was to evaluate the overall response rate (ORR) after four cycles. Patients Histological diagnosis of non-GCB DLBCL (Hans algorithm) with relapsed or refractory disease and non-candidates for autologous stem cell transplantation. Design Induction treatment with six (in cases of complete remission [CR] after cycle 4) or eight (in cases of partial response [PR] or stable disease after cycle 4) cycles of R-GEMOX-D at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years. Results Sixty-four patients (median age 67 [25–84] years) were included. Patients had received a median of two previous lines of treatment; 61% were refractory ( 10% of patients) were thrombocytopenia (51.6%), neutropenia (46.9%), anemia (21.9%), and diarrhea (15.6%). Conclusions The combination of ibrutinib with R-GEMOX-D is associated with high response rates, especially in non-refractory patients. The vast majority of refractory patients progress very early, so this regimen could be considered as a bridge to other consolidation therapies. Biological studies analyzing cell of origin by gene expression profiling, minimal residual disease, and mutational spectrum are in progress. Funding Janssen (NCT02692248)
Full Text via ClinicalKey